This site uses cookies to provide you with a more responsive and personalised service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print page


    Page   1/3   
  • Pharmaceutics Anti-Counterfeiting
    Counterfeited drugs are not only an issue in developing countries but also in the western world.
  • 2014 Global life sciences outlook
    The report outlines the top issues facing global life sciences stakeholders, provides a snapshot of activity in a number of geographic markets, and suggests considerations for companies as they seek to grow revenue and market share in 2014 and beyond.
  • Best in class product packaging for Life Sciences
    Innovative packaging concepts are perceived as a significant value contributor to improve patient adherence and safety.
  • Serialisation isn’t optional...
    Protect your patients, Product Revenue and Brand Reputation along your Supply Chain through serialisation. The need to protect drug products globally is increasing.
  • Measuring the return from pharmaceutical innovation 2013
    For the last four years Deloitte and Thomson Reuters have analysed the performance of the top 12 life sciences companies by estimating the projected financial returns from the investment in their late stage pipelines.
  • Growth and profitability under pressure
    Deloitte´s approach to growth and profitability comprises of key strategic measures designed to counter market challenges and maximise both top- and bottom-line benefits.
  • Working differently to provide early diagnosis
    A UK Deloitte Centre for Health Solutions report which examines how healthcare commissioners and providers can work differently with the diagnostic industry and other providers to increase early diagnosis.
  • Impact of European Austerity on Pharmaceutical policy and pricing
    A UK Deloitte Centre for Health solutions report that looks to understand the current European pharmaceutical market, the mechanisms for reducing pharmaceutical spending, the future of the pharmaceutical landscape, and the actions the pharmaceutical industry needs to take to survive current austerity.
  • PLM Governance and Organizational Alignment
    Prior to, during and after a PLM program
  • Product Life Cycle Management in Life Sciences Industry
    Evolving from siloed to cross-functional management.
  • Page   1/3   
Stay connected
Get connected
Share your comments